technologynetworks

Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl® to Further Help Prostate Cancer Patients

Once approved, Decapeptyl® 6-month formulation will be marketed by Debiopharm’s partners, such as Ipsen in most European Union countries. “This submission in Europe of our first 6-month-formulation ...
JSTOR Daily

Effects of Long-Term Treatment with the Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Decapeptyl and the LHRH Antagonist Cetrorelix on the Levels of Pituitary LHRH ...

This is a preview. Log in through your library . Abstract The effects of depot formulations of the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl (25 µg/day) for 30 days or LHRH ...
elEconomista

Ipsen announces the filing of Decapeptyl® 6?month formulation for the treatment of locally advancedor metastatic prostate cancer in Europe

Ipsen (Euronext: FR0010259150; Paris: IPN) today announced the start of the filing process in Europe of the 6–month sustained release formulation of Decapeptyl ®, a luteinizing hormone releasing ...
Reuters

Ipsen submits Decapeptyl version for European approval

PARIS, Sept 25 (Reuters) - Ipsen has submitted a six-month sustained version of its prostate cancer treatment Decapeptyl for marketing approval with European health authorities, the French drugmaker ...
Reuters

Ipsen registers new Decapeptyl version in Europe

PARIS, Oct 13 (Reuters) - Ipsen has completed the marketing approval registration in nine European countries for a six-month sustained version of prostate cancer treatment Decapeptyl, the French ...